Support for biospecimen access
In response to the Covid-19 crisis, biotech and pharma companies need to find biospecimens and associated information from Covid-19 patients without delay, for the development of drugs, diagnostics and vaccines. Placing these companies in direct contact with suitable academic biobanks and hospital providers will help communication and facilitate research.
Non-commercial biosample providers that want to connect with industry researchers seeking materials from Covid-19 infected patients are invited to join Biosample Hub.
Industry researchers that want to connect with non-commercial biosample providers to obtain materials from Covid-19 infected patients are also invited to join Biosample Hub.
Other Points Of Contact
The following centres also provide support for requesters and providers of Covid-19 biospecimens:
International Safety Guidelines
Please check your national/local regulations and guidelines for working with materials that are potentially infected with Covid-19. These may vary. The following guidelines may be applicable in your country/region:
- CDC Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Covid-19
- UCSF Guidelines for Research Biospecimens during the COVID-19 Outbreak
- Public Health England Guidance on COVID-19: safe handling and processing for samples in laboratories
If you have additional links to include on this page, please submit them in a message below.